Completed PHASE2 INTERVENTIONAL 2-arm NCT02343978

Phase II Study of KWA-0711 in Patients With Chronic Constipation (CC)

Phase II, Randomized, Open-label Study of KWA-0711 Administrated Orally for 2 Weeks to Evaluate Its Safety and Efficacy in Patients With Chronic Constipation (CC)

Sponsor: Kissei Pharmaceutical Co., Ltd.

Conditions Chronic Constipation

Interventions KWA-0711

Updated 6 times since 2017 Last updated: May 18, 2017 Started: Dec 26, 2014 Primary completion: May 1, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Chronic Constipation and is currently completed. Kissei Pharmaceutical Co., Ltd. leads this study, which shows 6 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jun 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2017 [monthly]

Completed PHASE2

First recorded

Dec 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kissei Pharmaceutical Co., Ltd.

Data source: Kissei Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tokyo, Japan